1. Wong J, et al. Harnessing the power of India. BCG Focus. 2006 May.
2. India biopharma product pipeline swells. BioSpectrumAsia. 2007 Nov 26.
3. Buchanan JM. Pharmaceutical patents in India: new and old compulsory license provisions cast doubt on their value. Available
4. The Patents (Amendment) Act, 2005. Available from patentoffice.nic.in/ipr/patent/patent_2005.pdf.
5. McNeil D. Indian company to make generic version of flu drug Tamiflu. New York Times. 2005 Oct 14.
6. Gerhardsen T. Indian industry pushing for compulsory licensing for Tamiflu. Intellectual Property Watch. 2007 Oct 25.
7. Srinivasan S. Battling patent laws: the Glivec case. Economic and Political Weekly. 2007 Sept 15;3686–90.
8. Mueller J. Taking TRIPS to India—Novartis, patent law, and access to medicines. New Eng J Med. 2007 Feb 8;346:541–43.
9. Lingh S, et al. Viread: the next pre-grant opposition target. 2006 May 23. Available from
10. Factor M, Indian generic pharma companies delay patent protection by pre grant opposition proceedings. The IP Factor.
2006 Oct 25. Available from
11. Gentleman A, H Kumar. AIDS groups in India sue to halt patent for US drug. New York Times. 2006 May 12.
12. Smith A, India's elephant in the room: weak patent laws.
http://CNN-Money.com/. 2007 May 4. Available from
http://www.money.cnn.com/2007/05/04/news/companies/india_biotech/index.htm (accessed 20 Oct 2007).
13. US Official Slams India's IP Laws. Managing Intellectual Property. 2006 Dec 11. Available from
14. Clearstate Pte. Ltd. Biotech: India's new global pitch. 2007 July 23. Available from
15. Finston S. Technology transfer: impact and importance for Indian biotechnology growth. Advances in Biopharmaceutical
Technology in India, ed. E Langer.
16. China, Russia upbraided in global intellectual property watchlist. Global Insight. Available from
17. Chhonkar V. India retained on US 'Special 301' watch list. Patent Circle. 2006 May 2. Available from
18. USTR priority watch list. Available from